Articles By Md Yuzaiful Md Yusof, MRCP(UK), PhD
Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE
By Md Yuzaiful Md Yusof, MRCP(UK), PhD
22 November 2021
It is almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under emergency use authorization (EUA). The question still being asked is whether the vaccine is safe for people with lupus?
Read Article
Emapalumab for the treatment of macrophage activation syndrome
By Md Yuzaiful Md Yusof, MRCP(UK), PhD
12 November 2021
Macrophage activation syndrome (MAS) is a term commonly used by rheumatologists to describe a potentially life-threatening complication of systemic inflammatory disorders, most commonly occurring in people with systemic juvenile idiopathic arthritis (sJIA) and systemic lupus erythematosus (SLE).
Read Article
Risks associated with mortality in VEXAS
By Md Yuzaiful Md Yusof, MRCP(UK), PhD
09 November 2021
Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) took the centre stage when it was first introduced at ACR20 last year. It got everyone’s thinking that they might have encountered one or two patients in their rheumatology lifetime who might have this condition.
Read Article
Do B-cell targeted therapies still have a place for the treatment of Sjogren’s?
By Md Yuzaiful Md Yusof, MRCP(UK), PhD
18 June 2021
B-cells play a major role in the pathogenesis of primary Sjogren’s syndrome (pSS) through antibody-dependent and antibody-independent functions, as well as evident by progression to B-cell malignancies/lymphoma. Hence, targeting B-cell is attractive. Despite efficacy of B-cell depleting therapy with rituximab in Phase II trials and case series, it failed to meet its primary endpoint when investigated in two Phase III trials. It is worth noting that the primary endpoint used in both trials was a subjective measure. Post-hoc analyses however showed greater improvement in objective measures such as salivary flow rate and salivary gland ultrasound score in RTX-treated group vs placebo. Therefore, do B-cell targeted therapies still have a place for the treatment of pSS?
Read Article
Promising options to treat mucocutaneous disease in SLE
By Md Yuzaiful Md Yusof, MRCP(UK), PhD
08 June 2021
Cutaneous lupus erythematosus (CLE) consists of a wide range of dermatologic manifestations seen in people with or without systemic lupus erythematosus (SLE). CLE can be categorised into LE-specific lesions, i.e.
Read Article